Newron’s ressurection story continues with a FDA Orphan Drug designation

14/07/2015 - 2 minutes

New success for Newron Pharmaceuticals. The FDA approved Orphan Drug designation to its new chemical entity Sarizotan, designed to treat patients suffering from Rett syndrome. This decision fits the one from the European Medicine Agency, whose Committee for Orphan Medical Products positively reviewed the drug last month.

The Italian pharma company Newron with a market capitalization of €400M seems entirely recovered from its toughest period, which took place back in 2011. Its lead Parkinson drug Xadago failed at that time in Phase III due to organizational problems and the break down caused the partner Merck to retire from the collaboration concerning this drug.

Newron’s candidate Sarizotan, licensed from Merck, is designed to treat the rare Rett syndrome, a neurodevelopmental disease that leads to impairments in fine and gross motor skills. Preclinical testing demonstrated that the drug led to a 70 to 85% reduction of apneas and hyperventilation episodes, one of the main symptoms of Rett syndrome.

Saratozin’s clinical development program is pushed in the States, Canada and also in Europe,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member